DOCSLIB.ORG

Clinically Relevant Molecular Subtypes in Leiomyosarcoma Xiangqian Guo1, Vickie Y

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinically Relevant Molecular Subtypes in Leiomyosarcoma Xiangqian Guo1, Vickie Y Published OnlineFirst April 20, 2015; DOI: 10.1158/1078-0432.CCR-14-3141 Biology of Human Tumors Clinical Cancer Research Clinically Relevant Molecular Subtypes in Leiomyosarcoma Xiangqian Guo1, Vickie Y. Jo2, Anne M. Mills3, Shirley X. Zhu1, Cheng-Han Lee4, Inigo Espinosa5, Marisa R. Nucci2, Sushama Varma1, Erna Forgo1, Trevor Hastie6, Sharon Anderson1, Kristen Ganjoo7, Andrew H. Beck8, Robert B. West1, Christopher D. Fletcher2, and Matt van de Rijn1 Abstract Purpose: Leiomyosarcoma is a malignant neoplasm with histochemical markers; LMOD1 for subtype I leiomyosar- smooth muscle differentiation. Little is known about its molec- coma and ARL4C for subtype II leiomyosarcoma. A leiomyo- ular heterogeneity and no targeted therapy currently exists for sarcoma tissue microarray with known clinical outcome leiomyosarcoma. Recognition of different molecular subtypes was used to show that subtype I leiomyosarcoma is associ- is necessary to evaluate novel therapeutic options. In a previous ated with good outcome in extrauterine leiomyosarcoma study on 51 leiomyosarcomas, we identified three molecular while subtype II leiomyosarcoma is associated with poor subtypes in leiomyosarcoma. The current study was performed prognosis in both uterine and extrauterine leiomyosarcoma. to determine whether the existence of these subtypes could be The leiomyosarcoma subtypes showed significant differ- confirmed in independent cohorts. ences in expression levels for genes for which novel targeted Experimental Design: Ninety-nine cases of leiomyosarcoma therapies are being developed, suggesting that leiomyosar- were expression profiled with 30end RNA-Sequencing (3SEQ). coma subtypes may respond differentially to these targeted Consensus clustering was conducted to determine the optimal therapies. number of subtypes. Conclusion: We confirm the existence of 3 molecular sub- Results: We identified 3 leiomyosarcoma molecular sub- types in leiomyosarcoma using two independent datasets and types and confirmed this finding by analyzing publically show that the different molecular subtypes are associated available data on 82 leiomyosarcoma from The Cancer with distinct clinical outcomes. The findings offer an opportu- Genome Atlas (TCGA). We identified two new formalin-fixed, nity for treating leiomyosarcoma in a subtype-specific targeted paraffin-embedded tissue-compatible diagnostic immuno- approach. Clin Cancer Res; 1–11. Ó2015 AACR. Introduction of leiomyosarcoma originates in various soft tissue sites where it is thought to often arise from smooth muscle cells Leiomyosarcoma is reported to represent as many as 24% of in vessel walls. all sarcomas (1, 2). Currently, no targeted therapy exists for The successful stratification of several tumors (including leiomyosarcoma and the tumor responds poorly to conven- breast cancer, lung cancer, and colon cancer) into molecular tional chemotherapy or radiotherapy. A significant proportion subtypes in the past decades has significantly improved our of leiomyosarcoma originates in the uterus, and the remainder knowledge of these malignancies and has led to changes in the therapeutic approach to these cancers (3–12). In a previous 1Department of Pathology, Stanford University School of Medicine, study, our group proposed the existence of three molecular Stanford, California. 2Department of Pathology, Brigham and subtypes of leiomyosarcoma by using microarray-based gene Women's Hospital and Harvard Medical School, Boston, Massachu- expression profiling on 51 fresh frozen samples of leiomyo- setts. 3Department of Pathology, University of Virginia, Charlottesville, Virginia. 4Division of Anatomical Pathology, Royal Alexandra Hospital, sarcoma (13). To validate this finding, we analyzed 99 leio- Edmonton, Alberta, Canada. 5Department of Pathology, Hospital de la myosarcoma cases collected at different institutions from the Santa Creu i Sant Pau, Autonomous University of Barcelona, Barce- 6 years 1991 to 2012 as an independent cohort, and performed lona, Spain. Department of Statistics, Stanford University, Stanford, fi 0 California. 7Stanford Comprehensive Cancer Center, Stanford Univer- expression pro ling with 3 end RNA sequencing (3SEQ; sity, Stanford, California. 8Department of Pathology, Beth Israel refs. 14–20). In addition, we analyzed the publically available Deaconess Medical Center and Harvard Medical School, Boston, expression profiling dataset from TCGA on 82 cases. Our ana- Massachusetts. lysis confirms the existence of three molecular subtypes in Note: Supplementary data for this article are available at Clinical Cancer leiomyosarcoma. Using two novel markers, we could distin- Research Online (http://clincancerres.aacrjournals.org/). guish the three subtypes by immunohistochemistry and corre- Corresponding Author: Matt van de Rijn, Department of Pathology, Stanford late the subtypes with clinical outcome. The recognition of University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305. Phone: these molecular subtypes in leiomyosarcoma may have clinical 650-498-7154; Fax: 650-723-1950; E-mail: [email protected] significance as the subtypes vary in their expression of a number doi: 10.1158/1078-0432.CCR-14-3141 of genes for which novel targeted therapies either already exist Ó2015 American Association for Cancer Research. or are being developed. www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2015 American Association for Cancer Research. Published OnlineFirst April 20, 2015; DOI: 10.1158/1078-0432.CCR-14-3141 Guo et al. of contingency analysis between one subtype and the other Translational Relevance 2 subtypes was measured by two-tailed Fisher exact test and c test Leiomyosarcoma is a malignant neoplasm with varying with GraphPad Prism5 software. Univariate and multivariate degrees of smooth muscle differentiation and complex genet- analysis by the Cox proportional hazard method was performed ic abnormalities. It can occur in a wide range of sites but is using the survival package in R. Analysis of gene ontology (GO) usually managed as a single disease in conventional therapy was done using DAVID Bioinformatics Resources version 6.7 and in clinical trials. The recognition of molecular subtypes (25, 26). CSF1-signature (27) positive, and CINSARC signature can lead to the identification of novel therapies that may (28) positive cases were identified as those cases that coordi- affect one of these subtypes preferentially. We confirmed nately highly expressed these signature genes with >0.3 correla- the results of an earlier study and determined the existence tion with the centroid as performed previously (19, 27, 29, 30). of 3 molecular subtypes in leiomyosarcoma using two Principal component analysis (PCA) was performed on square independent cohorts. We identified two new formalin-fixed, root transformed TPM with R package pcaMethods, ellipse con- paraffin-embedded (FFPE) tissue-compatible diagnostic tour of principal components (PC) was computed and drawn immunohistochemical markers for two of these subtypes: with R package car. LMOD1 for subtype I and ARL4C for subtype II, and showed that these molecular subtypes are associated with distinct TMA construction, immunohistochemistry staining, and clinical outcomes. Our study offers an opportunity for a scoring leiomyosarcoma subtype–specific targeted treatment. The tissue microarrays used in this study (TA-201 and TA-381) were constructed with Tissue Arrayer (Beecher Instru- ments). TA-201 included the leiomyosarcoma cases with clinic outcome data, while TA-381 was comprised of leiomyosarcoma Materials and Methods cases analyzed by 3SEQ. For immunohistochemical staining, sections underwent antigen retrieval and were stained with 3SEQ library construction and bioinformatics analysis anti-ARL4C antibody (1:120, Sigma, CAT#HPA028927) and fi Paraf n blocks of 99 leiomyosarcomas, 4 myometrium, 3 anti-LMOD1 antibody (1:20, Sigma, CAT#HPA028325) with leiomyoma, and 6 undifferentiated pleomorphic sarcomas from the EnVisionþsystem (Dako). The staining results were scored 1991 to 2012 from 9 hospitals were obtained with Institutional as follows: 3 (þþþ), strong staining (>30% positivity); 2 (þþ), review board approval and a waiver of consent due to the archival weak staining (10%–30%); 1 (þ), equivocal or uninterpretable nature of the specimens. Multiple 2 mm-diameter cores were re- (<10%); 0 (À), absence of any staining. Hierarchical clustering fi embedded into paraf n blocks longitudinally and sectioned of immunohistochemical (IHC) results was performed with again to ensure the purity of tumor cells. After RNA isolation, software "Cluster3" with "uncentered Correlation" and "Cen- – 3SEQ libraries for next-generation sequencing based expression troid Linkage" and a clustered heatmap was visualized with fi pro ling were sequenced and analysis was performed as described Java TreeView (31, 32). previously (14–20). All gene expression profiling data used for this study have been deposited in the Gene Expression Omnibus (GEO) and are publicly accessible through GSE45510, GSE53844 Results and GSE54511. Consensus clustering identifies three molecular subtypes of After filtering data to genes with a SD greater than 100, trans- leiomyosarcoma based on gene expression data forming the data by log2 and gene-based centering, the Consensus We analyzed 99 cases of leiomyosarcoma by 3SEQ, a next- Clustering (R package ConsensusClusteringPlus; ref. 21) was used generation sequencing–based approach that quantifies the to determine the number of subtypes and
Load more

Recommended publications
  • Increased Expression of the Tail-Anchored Membrane Protein SLMAP in Adipose Tissue from Type 2 Tally Ho Diabetic Mice
    Hindawi Publishing Corporation Experimental Diabetes Research Volume 2011, Article ID 421982, 10 pages doi:10.1155/2011/421982 Research Article Increased Expression of the Tail-Anchored Membrane Protein SLMAP in Adipose Tissue from Type 2 Tally Ho Diabetic Mice Xiaoliang Chen1 and Hong Ding2 1 Second People Hospital of Hangzhou, No. 1 Wenzhou Road, Hangzhou 310015, China 2 Department of Pharmacology, Weill Cornell Medical College in Qatar, P.O. Box 24144, Doha, Qatar Correspondence should be addressed to Hong Ding, [email protected] Received 6 April 2011; Accepted 5 May 2011 Academic Editor: N. Cameron Copyright © 2011 X. Chen and H. Ding. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The tail-anchored membrane protein, sarcolemmal membrane associated protein (SLMAP) is encoded to a single gene that maps to the chromosome 3p14 region and has also been reported in certain diabetic populations. Our previous studies with db/db mice shown that a deregulation of SLMAP expression plays an important role in type 2 diabetes. Male Tally Ho mice were bred to present with either normoglycemia (NG) or hyperglycemia (HG). Abdominal adipose tissue from male Tally Ho mice of the HG group was found to have a significantly lower expression of the membrane associated glucose transporter-4 (GLUT-4) and higher expression of SLMAP compared to tissue from NG mice. There were 3 isoforms expressed in the abdominal adipose tissue, but only 45 kDa isoform of SLMAP was associated with the GLUT-4 revealed by immunoprecipitation data.
    [Show full text]
  • ID AKI Vs Control Fold Change P Value Symbol Entrez Gene Name *In
    ID AKI vs control P value Symbol Entrez Gene Name *In case of multiple probesets per gene, one with the highest fold change was selected. Fold Change 208083_s_at 7.88 0.000932 ITGB6 integrin, beta 6 202376_at 6.12 0.000518 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 1553575_at 5.62 0.0033 MT-ND6 NADH dehydrogenase, subunit 6 (complex I) 212768_s_at 5.50 0.000896 OLFM4 olfactomedin 4 206157_at 5.26 0.00177 PTX3 pentraxin 3, long 212531_at 4.26 0.00405 LCN2 lipocalin 2 215646_s_at 4.13 0.00408 VCAN versican 202018_s_at 4.12 0.0318 LTF lactotransferrin 203021_at 4.05 0.0129 SLPI secretory leukocyte peptidase inhibitor 222486_s_at 4.03 0.000329 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 1552439_s_at 3.82 0.000714 MEGF11 multiple EGF-like-domains 11 210602_s_at 3.74 0.000408 CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 229947_at 3.62 0.00843 PI15 peptidase inhibitor 15 204006_s_at 3.39 0.00241 FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 202238_s_at 3.29 0.00492 NNMT nicotinamide N-methyltransferase 202917_s_at 3.20 0.00369 S100A8 S100 calcium binding protein A8 215223_s_at 3.17 0.000516 SOD2 superoxide dismutase 2, mitochondrial 204627_s_at 3.04 0.00619 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 223217_s_at 2.99 0.00397 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 231067_s_at 2.97 0.00681 AKAP12 A kinase (PRKA) anchor protein 12 224917_at 2.94 0.00256 VMP1/ mir-21likely ortholog
    [Show full text]
  • Role of SLMAP Genetic Variants in Susceptibility Of
    Upadhyay et al. Journal of Translational Medicine (2015) 13:61 DOI 10.1186/s12967-015-0411-6 RESEARCH Open Access Role of SLMAP genetic variants in susceptibility of diabetes and diabetic retinopathy in Qatari population Rohit Upadhyay1, Amal Robay2, Khalid Fakhro2, Charbel Abi Khadil2, Mahmoud Zirie3, Amin Jayyousi3, Maha El-Shafei4, Szilard Kiss5, Donald J D′Amico5, Jacqueline Salit6, Michelle R Staudt6, Sarah L O′Beirne6, Xiaoliang Chen7, Balwant Tuana8, Ronald G Crystal6 and Hong Ding1* Abstract Background: Overexpression of SLMAP gene has been associated with diabetes and endothelial dysfunction of macro- and micro-blood vessels. In this study our primary objective is to explore the role of SLMAP gene polymorphisms in the susceptibility of type 2 diabetes (T2DM) with or without diabetic retinopathy (DR) in the Qatari population. Methods: A total of 342 Qatari subjects (non-diabetic controls and T2DM patients with or without DR) were genotyped for SLMAP gene polymorphisms (rs17058639 C > T; rs1043045 C > T and rs1057719 A > G) using Taqman SNP genotyping assay. Results: SLMAP rs17058639 C > T polymorphism was associated with the presence of DR among Qataris with T2DM. One-way ANOVA and multiple logistic regression analysis showed SLMAP SNP rs17058639 C > T as an independent risk factor for DR development. SLMAP rs17058639 C > T polymorphism also had a predictive role for the severity of DR. Haplotype Crs17058639Trs1043045Ars1057719 was associated with the increased risk for DR among Qataris with T2DM. Conclusions: The data suggests the potential role of SLMAP SNPs as a risk factor for the susceptibility of DR among T2DM patients in the Qatari population.
    [Show full text]
  • Lineage-Defined Leiomyosarcoma Subtypes Emerge Years Before Diagnosis and Determine Patient Survival
    ARTICLE https://doi.org/10.1038/s41467-021-24677-6 OPEN Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival Nathaniel D. Anderson 1,2, Yael Babichev3,17, Fabio Fuligni4,17, Federico Comitani 1, Mehdi Layeghifard 1, Rosemarie E. Venier 3, Stefan C. Dentro5, Anant Maheshwari1, Sheena Guram3, Claire Wunker3,6, J. Drew Thompson1, Kyoko E. Yuki1, Huayun Hou 1, Matthew Zatzman1,2, Nicholas Light1,6, Marcus Q. Bernardini7,8, Jay S. Wunder 3,9,10, Irene L. Andrulis 2,3,11, Peter Ferguson7,9,10, Albiruni R. Abdul Razak7, Carol J. Swallow3,6,9,12, James J. Dowling1,11, Rima S. Al-Awar13,14, Richard Marcellus13, 1234567890():,; Marjan Rouzbahman2,7, Moritz Gerstung 5, Daniel Durocher 3,11, Ludmil B. Alexandrov 15, ✉ ✉ Brendan C. Dickson 2,3,16, Rebecca A. Gladdy 3,6,9,12 & Adam Shlien 1,2,4 Leiomyosarcomas (LMS) are genetically heterogeneous tumors differentiating along smooth muscle lines. Currently, LMS treatment is not informed by molecular subtyping and is associated with highly variable survival. While disease site continues to dictate clinical management, the contribution of genetic factors to LMS subtype, origins, and timing are unknown. Here we analyze 70 genomes and 130 transcriptomes of LMS, including multiple tumor regions and paired metastases. Molecular profiling highlight the very early origins of LMS. We uncover three specific subtypes of LMS that likely develop from distinct lineages of smooth muscle cells. Of these, dedifferentiated LMS with high immune infiltration and tumors primarily of gynecological origin harbor genomic dystrophin deletions and/or loss of dystrophin expression, acquire the highest burden of genomic mutation, and are associated with worse survival.
    [Show full text]
  • STRIPAK, a Highly Conserved Signaling Complex, Controls Multiple
    Biol. Chem. 2019; 400(8): 1005–1022 Review Ulrich Kück*, Daria Radchenko and Ines Teichert STRIPAK, a highly conserved signaling complex, controls multiple eukaryotic cellular and developmental processes and is linked with human diseases https://doi.org/10.1515/hsz-2019-0173 networks are now known to underlie the transmission and Received February 27, 2019; accepted March 28, 2019; previously modulation of such signals. These networks, controlled published online May 1, 2019 by diverse regulators at different cellular levels, are highly conserved across eukaryotic organisms. Abstract: The striatin-interacting phosphatases and Among the signaling components that have received kinases (STRIPAK) complex is evolutionary highly con- increased attention in the last decade is the STRIPAK served and has been structurally and functionally complex, which was initially identified in mammals by described in diverse lower and higher eukaryotes. In recent mass spectrometry (MS) analysis (Goudreault et al., 2009). years, this complex has been biochemically characterized Here we will provide a summary of the key studies leading better and further analyses in different model systems have to the discovery of striatin, the major regulatory phos- shown that it is also involved in numerous cellular and phatase subunit of the STRIPAK complex. Further, the developmental processes in eukaryotic organisms. Fur- components and architecture as well as the assembly and ther recent results have shown that the STRIPAK complex structural insights of the STRIPAK complex will be com- functions as a macromolecular assembly communicating prehensively reviewed. Another focus will be the control through physical interaction with other conserved signal- of developmental processes as a result of bi-directional ing protein complexes to constitute larger dynamic protein interaction of STRIPAK with other components involved networks.
    [Show full text]
  • UC San Diego Electronic Theses and Dissertations
    UC San Diego UC San Diego Electronic Theses and Dissertations Title Cardiac Stretch-Induced Transcriptomic Changes are Axis-Dependent Permalink https://escholarship.org/uc/item/7m04f0b0 Author Buchholz, Kyle Stephen Publication Date 2016 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, SAN DIEGO Cardiac Stretch-Induced Transcriptomic Changes are Axis-Dependent A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Bioengineering by Kyle Stephen Buchholz Committee in Charge: Professor Jeffrey Omens, Chair Professor Andrew McCulloch, Co-Chair Professor Ju Chen Professor Karen Christman Professor Robert Ross Professor Alexander Zambon 2016 Copyright Kyle Stephen Buchholz, 2016 All rights reserved Signature Page The Dissertation of Kyle Stephen Buchholz is approved and it is acceptable in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California, San Diego 2016 iii Dedication To my beautiful wife, Rhia. iv Table of Contents Signature Page ................................................................................................................... iii Dedication .......................................................................................................................... iv Table of Contents ................................................................................................................ v List of Figures ...................................................................................................................
    [Show full text]
  • Analysis and Functional Evaluation of the Hair-Cell Transcriptome
    Analysis and functional evaluation of the hair-cell transcriptome Brian M. McDermott, Jr.*, Jessica M. Baucom, and A. J. Hudspeth† Howard Hughes Medical Institute and Laboratory of Sensory Neuroscience, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399 Contributed by A. J. Hudspeth, May 17, 2007 (sent for review March 31, 2007) An understanding of the molecular bases of the morphogenesis, ciated from the lagena, a receptor organ of the zebrafish’s ear. organization, and functioning of hair cells requires that the genes Linear amplification of the RNA from 200 hair cells yielded Ϸ40 expressed in these cells be identified and their functions ascer- ␮g of aRNA, an enhancement of Ϸ1 millionfold. The resultant tained. After purifying zebrafish hair cells and detecting mRNAs labeled aRNA was hybridized to an Affymetrix microarray with oligonucleotide microarrays, we developed a subtractive (Affymetrix, Santa Clara, CA) containing Ϸ15,000 oligonucle- strategy that identified 1,037 hair cell-expressed genes whose otide probe sets. Averaging the outcomes of three experiments cognate proteins subserve functions including membrane trans- (SI Data Set 1) resulted in the identification of 6,472 transcripts port, synaptic transmission, transcriptional control, cellular adhe- scored as ‘‘present’’ (SI Data Set 2). sion and signal transduction, and cytoskeletal organization. To In the second step, we defined the transcriptome from cells of assess the validity of the subtracted hair-cell data set, we verified a nonsensory organ, the liver (SI Data Set 1). Hepatocytes were the presence of 11 transcripts in inner-ear tissue. Functional eval- selected for the subtraction process for three reasons: they are uation of two genes from the subtracted data set revealed their nonneuronal and thus unlikely to express synaptic factors; they importance in hair bundles: zebrafish larvae bearing the seahorse lack cilia (http://members.global2000.net/bowser/cilialist.html) and ift 172 mutations display specific kinociliary defects.
    [Show full text]
  • The Development and Pilot of a Quality Assurance Program for Proficiency
    Page 1 of 39 ins RCPAQAP Molecular Genetics Quality Use of Pathology Program Final Report Agreement id: 4-ALD5HVH July 2020 Title The development of a quality assurance pilot program for proficiency testing in cardiovascular disease Final Report A project funded under the Australian Government’s Quality Use of Pathology Program 1 Page 2 of 39 Contents List of Abbreviations 4 1. Executive Summary 5 2. Aims and Outcomes of the Study 8 2.1 Aims 8 2.2 Outcome 9 3. Background 10 4. Addressing Essential Needs 12 5. Benefits 13 6. Reference Samples 14 7. Methods 15 7.1 Laboratories 15 7.2 Reference testing of samples 15 7.3 Homogeneity and stability of the reference DNA 15 7.4 Whole genome DNA sequencing 15 7.5 Clinical data 15 7.6 Proficiency testing 16 8. Results and Discussion 17 8.1 Laboratories 17 8.2 Reference testing of samples 17 8.3 Homogeneity and stability 17 8.4 Whole genome DNA sequencing 18 8.5 Proficiency testing data 18 9. Project Findings 31 10. Problems Encountered 32 11. Future Diagnostics 33 12. Project Assessment 34 12.1 Short term 34 12.2 Intermediate term 34 12.3 Long term 34 12.3.1 Economy 34 12.3.2 Efficiency 35 12.3.3 Effectiveness 35 2 Page 3 of 39 13. Project Sustainability 36 14. Appendix 37 15. References 38 3 Page 4 of 39 List of abbreviations: CVD Cardiovascular disease DIN DNA Integrity Number EQA External quality assurance FH Familial hypercholesterolemia LDL Low-density lipoproteins NGS Next generation sequencing RCPAQAP Royal College of Pathologists of Australasia Quality Assurance Programs RPAH Royal Prince Alfred Hospital SNP Single nucleotide polymorphism 4 Page 5 of 39 1.
    [Show full text]
  • Milger Et Al. Pulmonary CCR2+CD4+ T Cells Are Immune Regulatory And
    Milger et al. Pulmonary CCR2+CD4+ T cells are immune regulatory and attenuate lung fibrosis development Supplemental Table S1 List of significantly regulated mRNAs between CCR2+ and CCR2- CD4+ Tcells on Affymetrix Mouse Gene ST 1.0 array. Genewise testing for differential expression by limma t-test and Benjamini-Hochberg multiple testing correction (FDR < 10%). Ratio, significant FDR<10% Probeset Gene symbol or ID Gene Title Entrez rawp BH (1680) 10590631 Ccr2 chemokine (C-C motif) receptor 2 12772 3.27E-09 1.33E-05 9.72 10547590 Klrg1 killer cell lectin-like receptor subfamily G, member 1 50928 1.17E-07 1.23E-04 6.57 10450154 H2-Aa histocompatibility 2, class II antigen A, alpha 14960 2.83E-07 1.71E-04 6.31 10590628 Ccr3 chemokine (C-C motif) receptor 3 12771 1.46E-07 1.30E-04 5.93 10519983 Fgl2 fibrinogen-like protein 2 14190 9.18E-08 1.09E-04 5.49 10349603 Il10 interleukin 10 16153 7.67E-06 1.29E-03 5.28 10590635 Ccr5 chemokine (C-C motif) receptor 5 /// chemokine (C-C motif) receptor 2 12774 5.64E-08 7.64E-05 5.02 10598013 Ccr5 chemokine (C-C motif) receptor 5 /// chemokine (C-C motif) receptor 2 12774 5.64E-08 7.64E-05 5.02 10475517 AA467197 expressed sequence AA467197 /// microRNA 147 433470 7.32E-04 2.68E-02 4.96 10503098 Lyn Yamaguchi sarcoma viral (v-yes-1) oncogene homolog 17096 3.98E-08 6.65E-05 4.89 10345791 Il1rl1 interleukin 1 receptor-like 1 17082 6.25E-08 8.08E-05 4.78 10580077 Rln3 relaxin 3 212108 7.77E-04 2.81E-02 4.77 10523156 Cxcl2 chemokine (C-X-C motif) ligand 2 20310 6.00E-04 2.35E-02 4.55 10456005 Cd74 CD74 antigen
    [Show full text]
  • Brugada Syndrome Genereview
    Title: Brugada Syndrome GeneReview – Less Common Genetic Causes Authors: Brugada R, Campuzano O, Sarquella-Brugada G, Brugada P, Brugada J, Hong K Updated: November 2016 Note: The following information is provided by the authors and has not been reviewed by GeneReviews staff. CACNA1C CACNA2D1 CACNB2 GPD1L HCN4 KCND3 KCNE3 KCNE5 (KCNE1L) KCNJ8 RANGRF SCN1B SCN2B SCN3B SLMAP TRPM4 CACNA1C Two other genes associated with the Brugada syndrome encode the α1 (CACNA1C) and β (CACNB2) subunits of the L-type cardiac calcium channel. The pathogenic variants in the α1 and β2b subunits of the cardiac calcium channel were often found to be associated with a familial sudden cardiac death (SCD) syndrome in which a Brugada syndrome phenotype is combined with shorter than normal QT secondary to a loss of function of the calcium channel current (ICa). Gene structure. The transcript variant NM_000719.6 comprises 47 exons. Multiple alternative transcripts have been described. Pathogenic variants Table 5. CACNA1C Pathogenic Variants Discussed in This GeneReview DNA Nucleotide Change Predicted Protein Change Reference Sequences 1 c.116C>T p.Ala39Val NM_000719.6 c.1468G>A p.Gly490Arg 1 NP_000710.5 Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants. Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature. 1. Antzelevitch et al [2007] Normal gene product. The genomic sequence encodes a protein of 2221 amino acids. CACNA1C encodes a number of isoforms of the pore-forming α1 subunit of the long- lasting (L-type) voltage-gated calcium channel (Cav1.2).
    [Show full text]
  • Disease-Relevant Transcriptional Signatures Identified in Individual
    Corrected: Publisher correction ARTICLE DOI: 10.1038/s41467-018-06891-x OPEN Disease-relevant transcriptional signatures identified in individual smooth muscle cells from healthy mouse vessels Lina Dobnikar1,2, Annabel L. Taylor 2, Joel Chappell2, Phoebe Oldach1,6, Jennifer L. Harman2, Erin Oerton 1,7, Elaine Dzierzak3, Martin R. Bennett2, Mikhail Spivakov 1,4,5 & Helle F. Jørgensen 2 1234567890():,; Vascular smooth muscle cells (VSMCs) show pronounced heterogeneity across and within vascular beds, with direct implications for their function in injury response and athero- sclerosis. Here we combine single-cell transcriptomics with lineage tracing to examine VSMC heterogeneity in healthy mouse vessels. The transcriptional profiles of single VSMCs con- sistently reflect their region-specific developmental history and show heterogeneous expression of vascular disease-associated genes involved in inflammation, adhesion and migration. We detect a rare population of VSMC-lineage cells that express the multipotent progenitor marker Sca1, progressively downregulate contractile VSMC genes and upregulate genes associated with VSMC response to inflammation and growth factors. We find that Sca1 upregulation is a hallmark of VSMCs undergoing phenotypic switching in vitro and in vivo, and reveal an equivalent population of Sca1-positive VSMC-lineage cells in atherosclerotic plaques. Together, our analyses identify disease-relevant transcriptional signatures in VSMC- lineage cells in healthy blood vessels, with implications for disease susceptibility, diagnosis and prevention. 1 Nuclear Dynamics Programme, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK. 2 Division of Cardiovascular Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. 3 MRC Centre for Inflammation Research, University of Edinburgh, Little France Crescent, Edinburgh EH16 4TJ, UK.
    [Show full text]
  • An In-Vivo Analysis of SLMAP Function in the Postnatal Mouse Myocardium
    An in-vivo analysis of SLMAP function in the postnatal mouse myocardium By: Taha Rehmani A thesis submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfillment of the requirements of the M.Sc. degree in Cellular and Molecular Medicine Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa, Ottawa, Ontario, Canada © Taha Rehmani, Ottawa, Canada, 2017 Abstract: SLMAP is a tail anchored membrane protein that alternatively splices to generate three isoforms, SLMAP1, SLMAP2 and SLMAP3. Previous studies in our lab have shown that the postnatal cardiac-specific overexpression of SLMAP1 results in intracellular vesicle expansion and enhanced endosomal recycling. I generated a postnatal cardiac-specific knockout model using the Cre-Lox system to nullify all three SLMAP isoforms and further evaluate its role in the mouse myocardium. SLMAP knockdown and knockout mouse hearts were analyzed with western blotting and qPCR. I found that only SLMAP3 was nullified and phenotypic evaluation through echocardiography indicated that young and old SLMAP3 knockout animals showed no remarkable changes in cardiac function. Furthermore, challenge with stressor isoproterenol had a similar response to wildtype and knockout mice in cardiac structure and function. Surprisingly the level of expression of SLMAP1 and SLMAP2 was maintained in the myocardium from SLMAP3 deficient mice. Interestingly the machinery involved in endosomal recycling was not impacted by the loss of SLMAP3. These data indicate that loss of SLMAP3 does not alter cardiac structure and function in the postnatal myocardium in the presence of SLMAP1 and SLMAP2. ii Table of Contents Chapter 1: Introduction ........................................................................................... 1 1.1 The mammalian heart structure and function ..........................................................
    [Show full text]